OSLI Retina

June 2020

Issue link: http://osliretina.healio.com/i/1260326

Contents of this Issue

Navigation

Page 61 of 63

368 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina News and Notes News and Notes Satralizumab Well Tolerated in Treatment of Neuromyelitis Optica Spectrum Disorder Pooled study data showed satralizumab for the treatment of neuromyelitis optica spectrum disorder was well tolerated as monotherapy or in combination with immunosuppressive therapy, according to a press release. The pooled data from the double-masked periods of the SAkuraStar and SAkuraSky phase 3 studies, presented virtually at the European Academy of Neurology meeting, showed rates of adverse events and serious adverse events were comparable between satralizumab and placebo groups when satralizumab was used as monotherapy or in combination with baseline immunosuppressive therapy. Additionally, the safety profile of satralizumab in the double-masked period of the studies was consistent with its open-label extension regarding the nature and rate of adverse events. A separate analysis of the SAkuraSky study found eight adolescents treated with satralizumab experienced a consistent benefit-risk profile when compared with an adult population. Adolescents were treated with the same adult dosing regimen of satralizumab 120 mg or placebo with baseline therapy at weeks 0, 2, and 4, and then every 4 weeks. Additionally, based on pharmacokinetic and pharmacodynamic analyses from phase 1 and the two phase 3 studies, data showed significant sustained interleu- kin-6 (IL-6) signaling inhibition with a once every 4 weeks dosing regimen of 120 mg satralizumab. For patients with NMOSD, a 120 mg dose of satralizumab allowed for more than 95% binding to the IL-6 receptor over the 4-week period. Originally posted on www.healio.com on May 28, 2020. Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2020. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $228, electronic only: $203. Institutional: One year—$719. Residents and fellows: $114 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $64 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $103. Payment must accompany order. Sub- scription requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS. Follow OSLIJournal OSLI Retina SLACK Incorporated 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-994-9900 Email: osli@healio.com Healio.com/OSLIRetina Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson SALES Chief Commercial Officer Matthew J. Holland Group Sales Director, Eye Care Scott Wright Senior Account Manager Kathy Huntley National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Sales Coordinator, Recruitment Jennifer Carroll Classified/Recruitment Sales KERH Group LLC 855-233-8100 slack@kerhgroup.com Reprints/Eprints Licensing Opportunities: Sheridan Content Solutions scsreprints@sheridan.com DESIGN Creative Director Thomas Cavallaro Production and Circulation Director Cheryl McKeown Production Associate Ryan Davis The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - June 2020